Financial Engines Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Financial Engines Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-955	Closed	-$596K	–	252
2020 Q2	$596K	Buy	955 +467	+96%	+$265K	﹤0.01%	125
2020 Q1	$238K	Buy	+488	New	+$201K	﹤0.01%	136
2018 Q1	–	Sell	-2	Closed	-$1K	–	208
2017 Q4	$1K	Buy	+2	New	+$810	﹤0.01%	198
2017 Q1	–	Sell	-204	Closed	-$75K	–	115
2016 Q4	$75K	Buy	+204	New	+$77.6K	﹤0.01%	58

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Financial Engines Advisors's REGN Position: Q3 2020 in Review

Financial Engines Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 955 shares — an estimated $596K sold.

Financial Engines Advisors first reported a position in REGN in Q4 2016 and held it in 4 quarters. The position peaked at $596K in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

Financial Engines Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Financial Engines Advisors sold 955 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $596K.
Financial Engines Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 4 quarters.
Financial Engines Advisors's Regeneron Pharmaceuticals position peaked at $596K in Q2 2020.
907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on Financial Engines Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.